We analyzed the microenvironmental changes in the PDA cohort of the trial (n = 6 with biopsy material before and after anti-CXCL12 therapy) and see that the only female of the patient group showed a clearly different local immune regulation. The gene discussed is CXCL12; the disease is Patent ductus arteriosus.